Salarius Pharmaceuticals' Seclidemstat Demonstrates Supporting Role in Inhibiting Validated Oncology Target LSD1 in Two Recently Published Studies

Stock Information for Salarius Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Salarius Pharmaceuticals Inc.

Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study
Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol "SLRX"
Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger
Strong Earnings and Biotech Resilience Define the Midweek Momentum
Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering
Salarius Pharmaceuticals Regains Compliance with All Nasdaq Listing Requirements
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq's Stockholders' Equity Standard

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.